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Summary Of patients being treated by radiotherapy for cancer, a small proportion develop marked long-term radiation damage. It is believed
that this is due. at least in part, to intrinsic individual differences in radiosensitivity, but the underlying mechanism is unknown. Individuals
affected by the recessive disease ataxia telangiectasia (AT) exhibit extreme sensitivity to ionizing radiation. Cells from such individuals are
also radiosensitive in in vitro assays, and cells from AT heterozygotes are reported to show in vitro radiosensitivity at an intermediate level
between homozygotes and control subjects. In order to examine the possibility that a defect in the ATMgene may account for a proportion of
radiotherapy complications, 41 breast cancer patients developing marked changes in breast appearance after radiotherapy and 39 control
subjects who showed no clinicalty detectable reaction after radiotherapy were screened for mutations in the ATMgene. One out of 41 cases
showing adverse reactions was heterozygous for a mutation (insertion A at NT 898) that is predicted to generate a truncated protein of 251
amino acids. No truncating mutations were detected in the control subjects. On the basis of this result, the estimated percentage (950o
confidence interval) of AT heterozygous patients in radiosensitive cases was 2.4% (0.1-12.9%) and in control subjects (0-9.0%). We
conclude that ATMgene defects are not the major cause of radiotherapy complications in women with breast cancer.
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For most solid tumours. curatixve radiotherapy inxolves deliverinn
a dose schedule at the limits of normal tissue tolerance. Most side-
effects lead to moderate functional impairment. but occasionallv
these are severe and even life-threatening (Maher Committee.
1995). The severitx of normal tissue reactions after a given course
of radiotherapy Xaries x idely from one patient to another. Severe
reactions can often in part be explained by radiotherapv technique
or by predisposing factors such as prior surgern. chemotherapy or
diabetes. Nexvertheless. exen after allowing for known factors.
considerable xariation still exists. The clearest evidence for this is
the xxork ofTuresson et al (1989. 1990). Thev measured earls and
late manifestations ofradiation skin damage under well-controlled
conditions in breast cancer patients. some of whom hax-e been
folloxwed up for oxer 10 y-ears. A standard treatment protocol was
found to produce xvery different degrees oftelangiectasia. ranging
from a barely detectable response to a sexere reaction. Analysis
of these clinical data by Tucker et al (1992) has suggested that
-ariation in tolerance between patients is determined by differ-
ences in Indixvidual intrinsic radiosensitivitv. exen among patients
wxho show no clinical symptoms of recognized radiosensitix e
sy-ndromes. An understanding of the basis of these interpatient
differences could lead to significant improvement in treatment by
the individualization ofthe radiotherapy prescription.
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Ataxia telangiectasia (AT) is an autosomal recessive disorder
that is characterized by cerebellar ataxia. oculocutaneous
telangiectasia and a predisposition to cancer (Boder and
Sedgxxick. 1958) Clinicallx. AT homozv5otes exhibit marked
hypersensitixitv to ionizing radiation. and fibroblasts or lympho-
cytes from AT homozygotes are highly radiosensitive in various
in vitro assays (Gotoff et al. 1967: Taylor et al. 1975: Weeks et
al. 1991: Jorgensen and Shiloh. 1996). Although AT itself is a
rare disease. it is estimated that approximately 1%c of individuals
in the general population are AT heterozvgotes (Easton. 1994:
Nagasaw-a et al. 1987). A number of in vitro studies have
suggested that cells from AT heterozvgotes may exhibit an inter-
mediate level of radiosensitivfitv between AT homozvyotes and
controls (West et al. 1995). Moreover. cells from patients
showing adxerse normal tissue damage after radiotherapy hax e
been shown to exhibit a dearee of cellular radiosensitivitv
similar to that of AT heterozgootes (Johansen et al. 1996). Taken
tooether these findings have led to the hypothesis that heterozv-
gosity for AT may account for some of the radiation complica-
tions obserx ed in clinical practice.
The AT gene (ATM) has recently been isolated (Saxvitsky et al.
1995). It is a large gene spanning approximately 200 kb of
genomic DNA x-ith a transcript size of approximately 10 kb
encoding a predicted protein of 3056 amino acids. The mutations
thus far discoxvered are highly heteroceneous. and are distributed
throughout the entire extent of the gene. The majority are null
mutations resulting in premature termination of translation (Byrd
et al. 1996: Gilad et al. 1996). In this study. xxe examined the
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Table 1 Treatment characteristcs of 835 patients with post-operative baseline photographs
Radiotherapy to whole breast
Radiotherapy to tumour bed (boost)
Boost (non-randomized)
Boost (randomized)
No boost (randomized)
Treatment to axilla
None
Radiotherapy (RT)
Surgery
RT + surgery
Adjuvant systemic therapy
None
Tamoxifen
Chemotherapy (CT)
Tamoxifen + CT
aFractions
association betw-een heterozyaosity for ATM gene defects and the
dexelopment of radiotherapy complications in breast cancer
patients.
MATERIALS AND METHODS
Study population
Between January 1986 and July 1994. 915 patients were entered
into a randomized trial comparing three fractionation regimens
after breast-preserving surgery for early-stage operable breast
cancer. All patients attended the Royal Marsden Hospital. Sutton.
or the Gloucestershire Oncology Centre. Cheltenham. A total of
835/915 (91%) patients had baseline post-operative photographs
of the breast. against which later radiation-induced changes
scored from photographs were compared on an annual basis. The
clinical and treatment characteristics of these 835 patients are
summarized in Table 1. At the time of assessment. 735 of these
had at least one follow-up photograph and made up the study
sample.
Radiotherapy
The duration of whole-breast radiotherapy was 5 w-eeks in all
arms. involving five treatments a fortnight for patients random-
ized to 13 fractions (3.0 Gy or 3.3 Gy per fraction) and five treat-
ments per w-eek for patients in the third arm (2.0 Gy per fraction).
Patients were treated in a supine position and most patients were
treated with 6-MV X-rays. The breast was encompassed by
opposed tangential fields using 15-30' wedges as tissue compen-
sators. Radiotherapy to the lymphatic pathways was included at
the discretion of the clinician depending on disease stage and
axillary surgery. An electron boost to the tumour bed of 14 Gy to
the 90% isodose in seven daily fractions was given to all patients
with cancer cells at the microscopic margins of resection. In
patients with complete microscopic resection of the primary
tumour. an option to randomize the boost (boost vs no boost) was
offered with patient consent. A boost was otherwise given
routinely.
Definition and assessment of end points
The pnrmary end point ofthe trial. which was used in this analysis.
relates to normal tissue responses in the breast as assessed by
serial photographs. Frontal photographs ofboth breasts were taken
after primary surgery and repeated annually for 5 years. All
photographs were reviewed by three independent observers (two
clinicians and one senior nurse) blind to patient identity. fractiona-
tion allocation and year offollow-up. Inclusion ofthe contralateral
breast at each time point made it possible to distinguish radio-
therapy effects from other time-related changes. e.g. w-eight gain.
Changes in breast appearance caused by radiotherapy were scored
on a three-point graded scale (none/minimal. 0: moderate. 1:
marked. 2) based on change in breast size and/or shape. usually
shrinkage. Inter- and intra-observer v-ariability were monitored by
comparing, scores between observers. All discrepancies between
observers were re-evaluated. Intra-observer variabilitv was evalu-
ated by assessing the reproducibility of scores for each obser er by
reassessing a random sample ofphotographs. Degree ofagreement
between scores was assessed using a weighted kappa statistic.
Case-control selection
Cases were defined as all individuals developing marked changes
(grade 2) at any time between 1 and 5 years post radiotherapy or
moderate changes (grade 1) scored for at least 3 years as assessed by
clinical photographs. We identified 56 patients in these categories.
41 ofwhom were available for study. Control subjects were defined
as individuals with no tissue reaction (grade 0) at the same time
since radiotherapy as the case experienced a reaction. We identified
39 control patients. matched as closely as possible for the factors
listed in Table 2. Written informed consent for genetic testing was
obtained from all patients (vwho remained alive) in the study.
Mutation detection
DNAs ere isolated from peripheral blood leucocvtes. All the indi-
viduals were screened for mutations using conformation sensitive
gel electrophoresis (CSGE) (Ganguly et al. 1993) of polvmerase
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50 Gy/25a
282
123
79
80
83
78
103
18
84
181
10
7
42.9 Gy/1 3a
270
123
74
73
88
68
91
23
93
156
11
10
39 Gy/13a
283
129
78
76
68
83
113
19
90
181
9
3
Totals
835
375
231
229
239
229
307
60
267
518
30
20
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Table 2 Clinical factors matched as closely as possible in 41 cases with
moderate or marked radiation damage and 39 control subjects without
detectable radiation damage
Radiotherapy fractionation schedule (50. 43. 39 Gy)
Radiotherapy breast boost (yes. no)
Year of scoring a normal tissue response (1-5 years)
Location of treating hospital (Sutton. Cheltenham)
Breast size (small. medium. large)
Radiotherapy field separation (- 1 cm)
Width of tangential radiotherapy field to breast (= 1 cm)
Thickness of lung incorporated in tangential fields (= 0.5 cm)
Axillary radiotherapy (yes. no)
Tamoxifen (yes. no)
Adjuvant chemotherapy (yes. no)
Timing of chemotherapy in relation to radiotherapy (concurrent. sequential)
chain reaction PCR) products covering the complete codinC
sequence and splicejunctions ofATM. The primers used are shown
in Table 3. For CSGE. both primers wxere radiolabelled usinc
'f 'P]ATP. Heteroduplexes were formed by heating the PCR prod-
ucts to 98-C for 10 min. holding at 60^C for 15 min and allowing to
return to room temperature. Samples were electrophoresed through
6%c polvacr lamide gels oxernight at 4 W. Fragments showing an
alteration in electrophoretic mobilitx were reamplified and directly
sequenced. using the ABI 377 automated DNA sequencer and the
ABI prism dye terminator cycle sequencing kit. with both forwxard
and reverse primers.
RESULTS
Sexeral sequence vaniants summarized in Table 4) wxere obserxed
in the course of the mutational screen of ATM. Of these. only one
x as predicted to generate a truncated protein. This mutation was an
insertion of A at nucleotide (nt) 898 in exon 8 and was hetero-
zygous. The predicted consequence is the production of a truncated
protein including the N-terminal 251 amino acids. a product only
8%7, of the normal size. This xariant wxas in a case xwith marked
(grade 2) radiotherapy changes in breast appearance. No truncating
mutations were detected in any of the 39 control subjects.
An additional radiosensitixe case was heterozvgous for a G-sA
transition at nt 4108 leading to substitution ofArg for GIv at amino
acid 1306. This sequence xariant was not found in the breast
cancer control subjects or in 147 healthys women. Gly 1306 is
conserxed in mouse ATV (mouse ATM is 95%7 identical to human
ATM) but is not within the kinase domain that shows substantial
similaritx to other members of this gene family. As 80-90%c of
ATTM mutations result in truncated proteins. at present it is difficult
to determine whether this is a rare innocuous polI morphism or a
mutation deleterious to ATM function.
Three other sequence xariants xere obserxed in a single case but
not in anx of the 39 control subjects. Two of these are intronic.
insertion T at nt 160-5 and G -* A at nt 2438 + 80. Neither of
these change consensual splice sequences and therefore are likely
to be rare polI-morphisms. The third alteration is a non-coding
change. C -*T at nt 7710 (Ala -* Ala).
Sexen sequence x-ariants xere detected in a sinale control but
not in any of the 41 cases. These include: twxo intronic chan,ces.
G -s T at nt 2088-39 and ins A at nt 3027 + 28: a xariant in
the 3' untranslated region. C -* G at nt 9389: txo non-coding
changes. T -* C at nt 5982 (Ala -* Ala) and G A at nt 7251
(Ala Ala): and two missense coding xariants G A at nt 7572
(Arg His) and C -s T at nt 8683 (gAr - His).
The remainder of sequence x ariants w-as observed in both cases
and control subjects and no substantial differences in heterozygote
frequency (as ascertained from CSGE gels) betu-een cases and
control subjects w-ere obserxved.
From these results the only sequence x-anant that is confidently
predicted to alter ATM function is the heterozygous insertion of A
at nucleotide 898 in exon 8.
DISCUSSION
A total of 80 patients 141 cases and 39 control subjects) selected
from 735 exaluable wromen with earlv breast cancer randomized
into a radiotherapy fractionation study were screened for muta-
tions in ATM. One out of 41 cases showved a typical mutation that
w-as predicted to generate a truncated protein (insertion A at
nucleotide 8981. This case had no other predisposing factors for
radiation damage and dexeloped marked breast shrinkage w-ith
moderate cutaneous telangiectasia following 39 Gv- in 13 fractions
(approximately equix alent to 46 Gy in 23 fractions of 2.0 Gyl. No
truncating mutations were detected in any of the 39 control
subjects. It is likelx that the mutational screening technique used
will miss a minoritv of mutations. particularl- of single base
substitutions and large genomic rearrangements. and therefore the
numbers reported may be underestimates. Nevertheless. the results
suggest that ATM mutations are unlikely to account for a substan-
tial proportion of patients with dose-limiting complications of
radiotherapy (although a small contribution cannot be excluded).
These results are consistent w-ith prexious reports of three AT
heterozvootes who had radiotherapy for breast cancer without
unusual reactions (Ramsav et al. 1996: Fitzcerald et al. 1997) and
16 breast cancer cases show-ing radiotherapy complications in
whom ATM mutations wxere not detected (Applebv et al. 1997).
From studies ofrelatix-es ofAT patients. there is exvidence that AT
heterozvgositv may be associated with an increased frequency of
certain types of cancer. particularly breast carcinoma (Swift et al.
1987. 1991: Pippard et al. 1988). Additional evidence supporting
this hypothesis has recently been obtained by genetic link-age
analyses of families of AT cases using mark-ers in the xicinitv of
ATM on chromosome 1 lq (Athma et al. 1996). However. direct
examination bv mutational screening of the ATM gene rexealed
mutations in 2/401 wAomen w-ith breast cancer compared with 2/202
control subjects (Fitzgerald et al. 1997). W'hereas these data do not
exclude a role for ATM as a low--penetrance breast cancer suscepti-
bility gene (Bishop and Hopper. 1997). they do not lend strong
support either. Although the present study is not a formal test ofthis
hypothesis because there is no matched control group and the
numbers are small. detection of a single AT heterozvoote in 80
breast cancer cases does not add further w-eight to the notion that
ATM is a low-penetrance breast cancer susceptibility gene.
Radiotherapy-induced breast shrinkage and distortion changres
in a proportion of women after radiotherapy are progressix e.
permanent and of clinical relexvance to the patient. They are also
clearly related to radiotherapy dose. In the clinical trial from w-hich
these patients are drawn. a 10%k difference in randomized dose
(42.9 Gv in 13 fractions vs 39 Gv in 13 fractions) w-as associated
with roughly a tw-ofold difference in the chance ofbreast shrinkage
(Owen et al. 1994). It has been shown in this study that testinc for
AT heterozygosity does not appear to offer a worthwhile approach
for the identification of the radiosensitive subgroup of breast
cancer patients and the search for the genetic loci responsible
should continue.
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Table 3 Oligonudeotde pnmers for ampirfication of individual ATMexons
Exon Nucleotide sequence (5-31) Size (bp) Nuceotide sequence (5'-3')
CTAGCCCTTFFFFIGATTGGC
CCTTTGACCAGAATGTGCCT
ATCTGCTTATCTGCTGCCGT
GCTC1TTGTGATGGCATGAA
AGTAGTTGCCATTCCAAGTGTC
CTGCGACCTGGCTCTTAAAC
AGTTTGTACAGTTTGTTCCCCC
GGTGTCTTCTAACGCTGATGC
GATACGAGATCGTGCTGTTCC
TGTTAATGTGATGGAATAGTTT
AAAGTCTrTGCCCCTCCAAT
TTCTTTACATGGCTTTTGGTCT
TCAAAGTCCGAAGAAGAGAAGC
AGCTATCCAGGATATGCCACC
TAAAAAGCAATACTAAACTA
TCTGCCGAGAATAATTG1TTTT
TGACTACAGCATGCTCCTGC
ATATGGCTGTTGTGCCCTTC
CGGCCTATGTTTATATACTT
TGTTCTTGAACTTCTGAAACCA
GCAAGGTGAGTATGTTGGCA
GAATGGCCCTAGTAAATTGCC
ATGCTTTGGAAAGTAGGG1TrG
AAAAATGTGGAGTTCAGTTGGG
TGTGTCAGATACTGTGCCAGTT
GCTGATGGTATTAAAACAGTTT
TGCCTTTTGAGCTGTCTTGA
AAATGGTTTTTGAA1TTGGGG
G IATTTCTAGGATTCCTATC
ATGCTGAACAAAAGGACTTCTG
TTCGCAACGTTATGGTGGTAT
TTTCACAGGCTTAACCAATACG
CAAAAAGTGTTGTCTTCATGCT
TTGACAACATTGGTGTGTAACG
ATGTATGATCTCTTACCTATGA
1TTGAAATITTTTCAGTGGAGG
GGAAAGGTACAATGATTTCCAC
CGGGGCATGAAAATT17AAG
CTGGGACTGAGGGGAGATA
GGGGAAATGTGGTTTFTGG
CAGGAGCTTCCAAATAGTATGT
CAGTTCAAACTCGTGTTG1TTG
GGAGCCAGATAG1TTGTATGGC
TCTCTGGTTT'TCTGTTGATATC
1TTGTCCTTTGGTGAAGCTATT
ATTTCCCTGAAAACCTCTTCTT
CCGCATAGCAT1TTGTAGGT
GGTAGNTGCTGC1TTCATTATT
GGGCAGTTGGGTACAGTCAT
CGTGGGTTGGACAAG1TTG
1TTCCCTGGGATAAAAACCC
CCACTTGTGCTAATAGAGGAGC
TGCAGGCATACACGCTCTAC
AAAGGCACCTAAGTCATTGACG
CTTGACCTTCAATGCTGTTCC
CACATCGCATTTGTTTCTCTG
ATTGG1TTGAGTGCCCTTTG
AGGTCAACGGATCATCAAATG
ATCCTGTTCATC1TTATTGCCC
CTCAACATGGCCGGTTATG
TGAGGAAGGCAGCCAGAG
TTGACAACATTGGTGTGTAACG
TCCCCCATCAACTACCATGT
CAAGGCCTTTAAACTGTTCACC
310
371
385
303
345
469
414
342
350
501
339
238
497
499
280
248
306
347
226
346
349
335
250
349
434
396
339
452
299
487
525
249
203
234
315
304
350
336
200
350
225
350
345
270
238
227
500
362
344
492
401
320
402
489
249
340
299
285
339
282
350
234
324
309
TGCTCATTCACTGATAGATGCA
ATCTCGAATCAGGCGCTTAA
ATGCCAAATTCATATGCAAGG
AAAAAAAAAAAAAACTCACGCG
AACTGTCAGGTCACTTGGGG
ATGGTCTTGCAAGATCAAAAGT
ATCAACCAGAGAAATCCAGAGG
CCCAAAATGCCCAGTTTAAA
GGATTCCACTGAAAGTTTTCTG
AATGATCAGGGATATGTGAGTG
AAATAAAGCCATCTGGCATCA
TAAGATGCAGCTACTACCCAGC
CCACCATCCTTGCTGTTTTT
TGCATGCTCTGCATCATGTA
CCAGGAGGTCAAGGCTACAATG
TGTTGTGAGATGCATCCTTATT
CAATGAGGCCTCTTATACTGCC
TCAAAGACACCATGTGATTCTT
GCTTAACAGAACACATCAGTT
TGCATTCGTATCCACAGATAGC
TCAGCCTACGGGAAAAGAAC
TCTACTGCCATCTGCAGCAT
TATGGGATATTCATAGCAAGCA
TGCCACTCAGAAAATCTAGCTT
GTTGCTGGTGAGGGGACTT
GTTATATCTCATATCATTCAGG
ATTACCTCAATTCAAAGGTGGC
GTGTCACGAGATTCTGTTCTCA
TATGTTA'TTACCTTTGGTTGA
TGGACTACCTCTCCACTTCAGC
CAGGCTGGTCTTGAACTCC
TCCCAAAATATTCTTTCCAAAA
TATGTGATCCGCAGTTGACTG
GCCACATCCCCCTATGTTAA
GCTTTAGTTACTGAGAATATCT
TTAACAGTCATGACCCACAGC
AACAACAGTTTGAGTGGGGG
TGGGATTCCATCTTAAATCCA
CATGTTAAAATTCAGCCGATAGTT
ACCCTTATTGAGACAATGCCA
GGCATCTGTACAGTGTCTATAA
AGCTTTGGGTTTTACACACACA
TCTGGCTGTGTAAATATCCACC
CAGTTGTTGTTTAGAATGAGGA
TTCAGAAAAGAAGCCATGACA
GGTAACAGAAAAGCTGCACTTT
CCTCAGGCTTTCTGTTTTTTAA
TTGCTAATTTCAAGGCTCTAAT
GTAACAATG1TTCACTCCACCC
TAAGCCGACCTTTAGAGCTCC
TACACGATTCCTGACATCAAGG
TTCCATTTCTTAGAGGGAATGG
CCAGCCTTGAACCGATT1TA
GGGAATGTTGAAGCCATCAG
TGCCAATA1TTAGCCAATTTTG
CAAAATCCCAAATAAAGCAGAA
ATTATGAATATGGGCATGAGCC
AGCTGTCAGCTTAATAAGCCA
CAAAAATAAAACCTGCCAAACA
CAAACAACATTCCATGATGACC
GTGCAAAGAACCATGCCC
GCCACATCCCCCTATGTTAA
GAACAGTTTAAAGGCCTTGGG
TTGGCAGGTTAAAAATAAAGGC
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8
9
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11
12
13
14
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20
21
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29
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33
34
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41
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Table 4 Summary of the ATsequence vanants detected. Numbering is according to the cDNA sequence deposited in Genbank as U33841
Intronic variants are described as ± the number of nucleotides from the nearest exonic base in the cDNA sequence
No. of heterozygotes No. of heterozygotes
Exon (E)Aintron (l) Location AA change out of thie 41 cases out of the 39 controls
12 160-5 insT None 1 0
E3 A201 G Val3Val 15 21
13 261-41 insAA None 11 14
E4 C 335 G Ser48 Cys 3 1
E8 898 lnsA Stop at codon 251 1 0
E8 C 924T Val 244Val 1 1
113 T2088-56G None 1 1
113 G 2088 -39 T None 0 1
115 G 2438 +80 A None 1 0
E18 T2761 C Phe857 Leu 1 1
119 3027 +28 insA None 0 1
121 T 3267 -80 C None 12 16
E23 C 3350G Pro 1053Arg 4 4
123 3473-13 delT None 6 5
E27 G 4108 A Gly 1306 Arg 1 0
E31 C 4767T Pro 1525 Pro 4 1
137 T 5686 -8 C None 5 6
E38 G 5746A Asp l852Asn 2 2
E40 T 5982 C Ala 1930 Ala 0 1
E40 G 6010 C Val 1940 Leu 3 1
147 6997-57 insATT None 12 19
E49 G 7251 A Ala 2353 Ala 0 1
E51 G 7572 A Arg 2460 His 0 1
E52 C 7710 T Ala 2506 Ala 1 0
E59 C 8683 T Arg 2830 His 0 1
162 A9039+60 G None 10 17
E64 C 9389 G None (3' untranslated) 0 1
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